The Difference Between Ipamorelin and GHRP-2

Ipamorelin and GHRP-2 are often confused with one another. Indeed, both have been hypothesized to lead to a growth hormone (GH) production surge. Studies suggest that GHRP-2 and Ipamorelin are completely distinct peptides; the one commonality between them is that they may both trigger the secretion of the GH hormone. A comparison between Ipamorelin and GHRP-2 is provided below, outlining the shared and unique aspects of the two research programs.

Ipamorelin and GHRP-2 have been theorized to stimulate the pituitary gland to discharge more growth hormone by linking to the growth hormone secretagogue receptor. This indicates that the two peptides may function similarly to ghrelin. The hunger hormone, or ghrelin, is a naturally occurring peptide that drives eating behavior and is generated in the gastrointestinal system, but that’s not all it can accomplish.


Various cognitive processes, including learning, memory, the circadian rhythm, glucose metabolism, taste perception, and reward behavior, are modulated by stimulating the growth hormone secretagogue receptor (GHS-R). First and foremost, activating this receptor affects the body’s energy balance by facilitating the transition from catabolism, the destruction of stored energy, to anabolism, the preservation of energy for use in repairing and constructing muscle and other tissues. This change happens when GH release is stimulated. Ipamorelin and GHRP-2 are peptides speculated to stimulate growth hormone release in a two-pronged manner since GHS-Rs are located in both the pituitary gland and the brain. Two mechanisms are hypothesized to be involved: the first is the direct stimulation of the pituitary gland, which stores growth hormone, and the second is the release of GHRH, which may stimulate the release of GH via its receptors on the pituitary gland.

The ghrelin axis is important because it may stimulate growth hormone secretion in two ways: first, by binding to GHS-Rs on the pituitary gland, and second, by binding to GHS-Rs in the brain, which triggers the growth hormone secretion. Analogs of ghrelin include GHRP-2 and Ipamorelin.

However, the change isn’t cut and dry since Ipamorelin and GHRP-2 might promote fat loss and muscle and bone cell growth. Consequently, research suggests they may alter the energy balance to defy easy categorization into catabolic and anabolic processes. Investigations purport that any peptide that promotes lean body mass may be thought of as stimulating the GHS-R, which is especially true of these peptides. Findings imply that although they are primarily fat-burning peptides possibly aiding muscle repair and growth, they may also have many other useful uses.

GHRP-2 and Ipamorelin: Appetite

Research suggests that potential appetite stimulants Ipamorelin and GHRP-2 may work similarly to ghrelin since they mimic the hormone. They have been hypothesized to encourage eating because of this. Intriguingly, activation of the GHS-R changes the kinds of food eaten and increases food consumption. As purported by studies, ghrelin, and its analogs encourage the consumption of lean-body-mass-promoting meals rather than sugary or fatty ones. The possibility that these peptides might aid in the battle against obesity has led to their investigation.

GHRP-2 and Ipamorelin: Sleep

Scientists speculate that GHRP-2 may enhance the quality of sleep. The length of rapid eye movement (REM) sleep appears to have increased by around 20% and the duration of phases 3 and 4 by approximately 50%, as suggested by research on GHRP-2. Cognitive performance, wound healing, vitality, and blood pressure have all been theorized to be aided significantly. Although findings imply that Ipamorelin may help promote sleep cycle regulation to a certain extent, studies suggest that GHRP-2 may significantly improve sleep quality by reducing irregular sleep patterns by up to one-third.

GHRP-2 and Ipamorelin: Pain

It turns out that GHRP-2 may assist in reducing pain by binding to an opioid receptor. Ipamorelin seems to have little impact on how research models perceive pain and has not suggested any such tendency. 

Research Synopsis

Animal studies have evaluated the potential impact of both Ipamorelin and GHRP-2; Ipamorelin has experimented in phase I and II studies in the context of postoperative ileus. Although the study was subsequently shelved, it sheds light on the peptide’s potential in drawn-out animal studies. Some areas of study interested in studying the peptide’s potential on animals could find this helpful.

Animals, including pigs and yaks, have been tested, but mice and rats are the main subjects of the study. This provides a solid foundation for future model studies with these peptides. Thus, there is a large body of trial data from which researchers may draw when planning experiments and predicting results related to these peptides.

Visit Core Peptides if you are a researcher interested in further studying these peptides. Please note that none of the substances mentioned in this article have been approved for human consumption and should, therefore, only be used by licensed professionals in contained laboratory environments.


[i] K. Raun et al., “Ipamorelin, the first selective growth hormone secretagogue,” Eur. J. Endocrinol., vol. 139, no. 5, pp. 552–561, Nov. 1998.

[ii] R. Hu et al., “Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation,” PloS One, vol. 11, no. 2, p. e0149461, 2016.

[iii] L. T. Phung et al., “The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine,” Domest. Anim. Endocrinol., vol. 18, no. 3, pp. 279–291, Apr. 2000.

[iv] “Why does HGH decline with Age? – | The Well-Being Institute.” 

[v] B. Laferrère, A. B. Hart, and C. Y. Bowers, “Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake,” Obes. Silver Spring Md, vol. 14, no. 6, pp. 1056–1063, Jun. 2006.

[vi] E. Adeghate and A. S. Ponery, “Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats,” Neuro Endocrinol. Lett., vol. 25, no. 6, pp. 403–406, Dec. 2004.

[vii] D. Yamamoto et al., “GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1,” Life Sci., vol. 82, no. 9–10, pp. 460–466, Feb. 2008.

[viii] N. K. Aagaard et al., “Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats,” Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc., vol. 19, no. 5, pp. 426–431, Oct. 2009.

Vivek is a published author of Meidilight and a cofounder of Zestful Outreach Agency. He is passionate about helping webmaster to rank their keywords through good-quality website backlinks. In his spare time, he loves to swim and cycle. You can find him on Twitter and Linkedin.